Literature DB >> 6203882

Regulation of expression of class II major histocompatibility antigens on human peripheral blood monocytes and Langerhans cells by interferon.

T Basham, W Smith, L Lanier, V Morhenn, T Merigan.   

Abstract

Although normal peripheral blood monocytes from different individuals are primarily DR+ (L243), they vary in the mean expression of L243 and the percentage of cells with detectable Leu-10 (DC/DS) and L03 (D). All three species of human recombinant IFNs enhance Ia expression on normal peripheral blood monocytes; however, r-IFN-gamma is much more effective in enhancing the expression of these three class II antigens in vitro than r-IFN-beta or r-IFN-alpha A. In addition, r-IFN-gamma has a more profound effect on the expression of Leu-10 (DC/DS), an antigen critical for presentation in autologous MLR, than on L243 (DR). Adherent monocytes cultured for 5 days develop macrophage characteristics and become strongly positive for all three of these class II antigens without further manipulation. Isolated skin Langerhans cells which are thought to be antigen presenting cells in the epidermis are also strongly positive for all three of these Ia antigens and are unaffected by IFN treatment. Therefore, this early interferon effect on cell surface expression may be the result of enhancing the maturation of monocytes to mature antigen presenting cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6203882     DOI: 10.1016/0198-8859(84)90075-2

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  10 in total

1.  Epstein-Barr virus entry utilizing HLA-DP or HLA-DQ as a coreceptor.

Authors:  K M Haan; W W Kwok; R Longnecker; P Speck
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Innate immune stimuli modulate bone marrow-derived dendritic cell production in vitro by toll-like receptor-dependent and -independent mechanisms.

Authors:  Joan E Downes; Stuart Marshall-Clarke
Journal:  Immunology       Date:  2010-12       Impact factor: 7.397

3.  Effect of gamma-interferon on lectin-binding glycoproteins in cultured human keratinocytes.

Authors:  A Reano; S Hesse; J Viac
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

4.  Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine.

Authors:  J H Nunberg; M V Doyle; S M York; C J York
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

5.  Comparison of phenotype expression by mononuclear phagocytes within subcutaneous gouty tophi and rheumatoid nodules.

Authors:  D G Palmer; N Hogg; I Denholm; C A Allen; J Highton; P A Hessian
Journal:  Rheumatol Int       Date:  1987       Impact factor: 2.631

6.  Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo beta-interferon.

Authors:  G T Spear; D M Paulnock; R L Jordan; D M Meltzer; J A Merritt; E C Borden
Journal:  Clin Exp Immunol       Date:  1987-07       Impact factor: 4.330

7.  The Fc receptor, FcRI, and other activation molecules on human mononuclear phagocytes after treatment with interferon-gamma.

Authors:  Y Jayaram; A M Buckle; N Hogg
Journal:  Clin Exp Immunol       Date:  1989-03       Impact factor: 4.330

8.  Innate-like CD4 T cells selected by thymocytes suppress adaptive immune responses against bacterial infections.

Authors:  Yu Qiao; Brian M Gray; Mohammed H Sofi; Laura D Bauler; Kathryn A Eaton; Mary X D O'Riordan; Cheong-Hee Chang
Journal:  Open J Immunol       Date:  2011-12-30

9.  Massive induction of donor-type class I and class II major histocompatibility complex antigens in rejecting cardiac allografts in the rat.

Authors:  A D Milton; J W Fabre
Journal:  J Exp Med       Date:  1985-01-01       Impact factor: 14.307

10.  In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon.

Authors:  C O Jacob; P H van der Meide; H O McDevitt
Journal:  J Exp Med       Date:  1987-09-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.